Product Pathways - Lymphocyte Signaling
Phospho-CD79A (Tyr182) (D1B9) Rabbit mAb (PE Conjugate) #14948
|14948S||100 µl ( 50 tests )||￥4,060.00||现货查询 购买询价 防伪查询|
|14948||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: F=Flow Cytometry,
Species predicted to react based on 100% sequence homology: Mouse,
Specificity / Sensitivity
Phospho-CD79A (Tyr182) (D1B9) Rabbit mAb (PE Conjugate) recognizes endogenous levels of CD79A protein only when phosphorylated on Tyr188, which corresponds to Tyr182 of mouse CD79A protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr188 of human CD79A protein. This sequence corresponds to Tyr182 of mouse CD79A protein.
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated Phospho-CD79A (Tyr182) (D1B9) Rabbit mAb #14732.
Antigen receptors found on the surface of B cells contain a heterodimeric signaling component composed of CD79A and CD79B, also known as Ig α and Ig β, respectively (1,2). Presence of this receptor complex is essential for B-cell development and function (3). Together these two proteins and the associated B cell receptor initiate intracellular signaling following antigen binding (4,5). An immunoreceptor tyrosine-based activation motif (ITAM) found in the CD79A intracellular region appears to be important for its function (6). Antigen binding precedes formation of the CD79A and CD79B heterodimer and subsequent activation of receptor associated kinases (7). Research has shown that CD79A is a marker for B-lineage lymphoblastic leukemia (8). Additionally, investigators have found that mutations in the CD79A (MB1) gene are associated with abnormally low levels of functional B cell receptors in some cases of chronic B cell lymphocytic leukemia (9).
- van Noesel, C.J. et al. (1991) J Immunol 146, 3881-8.
- Minegishi, Y. et al. (1999) J Clin Invest 104, 1115-21.
- Yu, L.M. and Chang, T.W. (1992) J Immunol 148, 633-7.
- Storch, B. et al. (2007) Eur J Immunol 37, 252-60.
- Mason, D.Y. et al. (1995) Blood 86, 1453-9.
- Luisiri, P. et al. (1996) J Biol Chem 271, 5158-63.
- Pike, K.A. et al. (2004) J Immunol 172, 2210-8.
- Astsaturov, I.A. et al. (1996) Leukemia 10, 769-73.
- Vuillier, F. et al. (2005) Blood 105, 2933-40.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条